Manage Future Cancer Risk, Inform Treatment Decisions Related to PARP Inhibitors1

Sources:

  1. Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 377:523-533